Vectura Group plc – Product Pipeline Review – Q4 2010

Date: November 1, 2010
Pages: 79
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: VB0088AF9F3EN
Leaflet:

Download PDF Leaflet

Vectura Group plc – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Vectura Group plc – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Vectura Group plc – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Vectura Group plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Vectura Group plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Vectura Group plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Vectura Group plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Vectura Group plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Vectura Group plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Vectura Group plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Vectura Group plc and identify potential opportunities in those areas.
Vectura Group plc Snapshot
Vectura Group plc Overview
Key Information
Key Facts
Vectura Group plc – Research and Development Overview
Key Therapeutic Areas
Vectura Group plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vectura Group plc – Pipeline Products Glance
Vectura Group plc – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Vectura Group plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Vectura Group plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Vectura Group plc – Drug Profiles
VR315
  Product Description
  Mechanism of Action
  R&D Progress
VR004
  Product Description
  Mechanism of Action
  R&D Progress
VR040
  Product Description
  Mechanism of Action
  R&D Progress
VR496
  Product Description
  Mechanism of Action
  R&D Progress
VR632
  Product Description
  Mechanism of Action
  R&D Progress
VR776
  Product Description
  Mechanism of Action
  R&D Progress
VR147
  Product Description
  Mechanism of Action
  R&D Progress
VR461
  Product Description
  Mechanism of Action
  R&D Progress
VR506
  Product Description
  Mechanism of Action
  R&D Progress
VR632
  Product Description
  Mechanism of Action
  R&D Progress
VR909
  Product Description
  Mechanism of Action
  R&D Progress
Vectura Group plc – Pipeline Analysis
Vectura Group plc – Pipeline Products by Therapeutic Class
Vectura Group plc Pipeline Products By Target
Vectura Group plc – Pipeline Products by Route of Administration
Vectura Group plc – Pipeline Products by Molecule Type
Vectura Group plc – Recent Pipeline Updates
Vectura Group plc - Dormant Projects
Vectura Group plc – Company Statement
Vectura Group plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 16, 2010: Vectura Reports Positive Outcome For VR040 In Phase II Parkinson’s Trial
Mar 18, 2010: Vectura And Sandoz Revise VR315 Agreement
Mar 18, 2010: Vectura And Sandoz Revise VR315 Agreement
Aug 13, 2009: Vectura Receives $6m Milestone Payment For VR315
Aug 13, 2009: Vectura Receives $6m Milestone Payment For VR315
Apr 21, 2009: Vectura Receives €2.5m Milestone Payment For VR315
Apr 21, 2009: Vectura Receives €2.5m Milestone Payment For VR315
Apr 15, 2008: Vectura announces positive data with inhaled anti-migraine product
May 23, 2007: Vectura Announces Clinical Proof Of Concept For Inhaled Premature Ejaculation Product
Apr 23, 2007: Vectura Announces Successful Outcome of Second Phase IIb Clinical Study on VR004
Financial Deals Landscape
Vectura Group plc, Deals Volume Summary, 2004 to YTD 2010
Vectura Group plc, Deals Summary By Region, 2004 to YTD 2010
Vectura Group plc, Deals Summary, 2004 to YTD 2010
Vectura Group plc Detailed Deal Summary
Asset Purchase
Celliance Acquires UCOE Gene Expression Technology From Innovata
Acquisition
Vectura Group Acquires Innovata
ML Laboratories Acquires Minority Interest In Innovata Biomed
ML Laboratories Acquires Quadrant Technologies
Venture Financing
PharmaKodex Secures $13.43 Million In Series A Financing
Equity Offering
Vectura Group Completes Private Placement Of $7.22 Million
Vectura Group Completes Private Placement Of $82.06 Million
Vectura Group Completes Private Placement Of $12.83 Million
ML Laboratories Completes Private Placement Of $45.88 Million
Vectura Group Completes Initial Public Offering Of $36.48 Million
Vectura Group Completes Private Placement Of $3.68 Million
Vectura Group Enters Into An Agreement With Pharmaceutical Company
Vectura Group Enters Into Licensing Agreement With Pharmaceutical Company
Vectura Signs An Agreement With Boehringer Ingelheim
Innovata Signs An Agreement With Baxter International
Innovata Enters Into Agreement With A Pharmaceutical Company
Vectura Group And Arakis Signs An Agreement With Novartis
Vectura Enters Into An Agreement With SkyePharma
Licensing Agreements
Vectura Group Enters Into Licensing And Collaboration Agreement With Sandoz
ML Laboratories Enters Into Licensing Agreement With Maxygen
ML Laboratories PLC Enters Into Licensing Agreement
ML Laboratories Amends Licensing Agreement With Crucell
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Vectura Group plc – Pipeline by Therapy Area and Indication, 2010
Vectura Group plc – Pipeline by Stage of Development, 2010
Vectura Group plc – Monotherapy Products in Pipeline, 2010
Vectura Group plc – Phase III, 2010
Vectura Group plc - Phase II, 2010
Vectura Group plc - Phase I, 2010
Vectura Group plc - Pipeline By Therapeutic Class, 2010
Vectura Group plc - Pipeline By Target, 2010
Vectura Group plc – Pipeline By Route of Administration, 2010
Vectura Group plc – Pipeline By Molecule Type, 2010
Vectura Group plc – Recent Pipeline Updates, 2010
Vectura Group plc - Dormant Developmental Projects, 2010
Vectura Group plc, Other Locations
Vectura Group plc, Subsidiaries
Vectura Group plc, Deals Summary, 2004 to YTD 2010
Vectura Group plc, Deals Summary by Region, 2004 to YTD 2010
Vectura Group plc, Deals Summary, 2004 to YTD 2010 46

LIST OF FIGURES

Vectura Group plc – Pipeline by Therapy Area and Indication, 2010
Vectura Group plc – Pipeline by Stage of Development, 2010
Vectura Group plc – Monotherapy Products in Pipeline, 2010
Vectura Group plc – Pipeline By Therapeutic Class, 2010
Vectura Group plc - Pipeline By Target, 2010
Vectura Group plc – Pipeline By Route of Administration, 2010 30

Ask Your Question

Vectura Group plc – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: